Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**25-deacetyl-rifabutin** is the major active metabolite of rifabutin, produced by hepatic metabolism. Like its parent molecule, it is an **antibiotic** of the rifamycin class, with activity against *Mycobacterium tuberculosis* and related species. Its antimicrobial effect is due to inhibition of DNA-dependent RNA polymerase in susceptible bacteria, resulting in suppression of RNA synthesis and cell death. Studies indicate the metabolite retains significant antimicrobial activity, showing additive effects when present with the parent drug, and contributing to the overall bactericidal action of rifabutin regimens[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 25-deacetyl-rifabutin.